Recently, a CEO Marc D. Beer raised approximately $42 million for the funding of a women’s health startup called Renovia, Inc. Renovia was formed to improve conditions of quality of life for women specifically with pelvic floor disorders. The company aims to advance diagnosis, treatment times and options for the millions of women who suffer from the disorder. The raised money is going to create more new products.
This Boston based company designs diagnostic and new products with effective treatments to help with, what researchers say, is a staggering 250 million women throughout the world living with pelvic floor disorders. Through the latest technology, monitoring the overall progress of each patient is done in real time. Also, Renovia is chasing more cost-effective care for the disorders. The FDA approved the first product that Renovia came out with, Leva device in April 2018.
A healthcare investment firm, The Longwood Firm, joined early with Renovia. Perceptive Advisors, based in New York and Ascension Ventures, based in Missouri were also part of the investments of Renovia. The Leva device is already being looked at in upgrading and making new advancements.
With more than 25 years of experience with diagnostics, medical devices and biotechnology all seen in marketing, Marc Beer has been extremely busy. He founded Renovia in August of 2016, and that has just been his recent acquisition.
In April of 2000, Marc Beer founded ViaCell and became CEO. ViaCell was a biotech company that studied and collected umbilical cord stem cells. For over seven years, Marc directed the company from its’ beginning stages to a healthy growing organization. In 2005, the company went public with more than 300 employees and in 2007 PerkinElmer acquired it.
While Marc Beer was CEO of ViaCell, he was on the board of directors at Erytech Pharma; this was another pharmaceutical company. Previously to ViaCell, he was Vice President of Global Marketing at Genzyme. In this position, he was in charge of launching a variety of products that had to deal with rare disease populations globally.
Before Genzyme, Marc Beer held different roles in Abbott Laboratories. He was a member of the Mass Life Science Board of the Commonwealth of Massachusetts and was on the board of Biotechnology Industry Organization.
Marc Beer has his BS from Miami University (Ohio). Including his education, Marc Beer has made a name for himself in biotechnology and the pharmaceuticals’ industry with all of his experience. Learn more: https://www.benzinga.com/pressreleases/18/08/r12237847/osf-ventures-invests-in-company-developing-solutions-for-pelvic-floor-